Significant attention has focused on the role of low-density lipoprotein (LDL) in the pathogenesis of atherosclerosis. However, recent advances have identified triglyceride-rich lipoproteins [e.g., very LDL (VLDL)] as independent risk predictors for this disease. We have previously demonstrated peroxisome proliferator-activated receptor (PPAR)␦, but not PPAR␥, is the major nuclear VLDL sensor in the macrophage, which is a crucial component of the atherosclerotic lesion. Here, we show that, in addition to ␤-oxidation and energy dissipation, activation of PPAR␦ by VLDL particles induces key genes involved in carnitine biosynthesis and lipid mobilization mediated by a recently identified TG lipase, transport secretion protein 2 (also named desnutrin, iPLA2, and adipose triglyceride lipase), resulting in increased fatty acid catabolism. Unexpectedly, deletion of PPAR␦ results in derepression of target gene expression, a phenotype similar to that of ligand activation, suggesting that unliganded PPAR␦ suppresses fatty acid utilization through active repression, which is reversed upon ligand binding. This unique transcriptional mechanism assures a tight control of the homeostasis of VLDL-derived fatty acid and provides a therapeutic target for other lipid-related disorders, including dyslipidemia and diabetes, in addition to coronary artery disease. At the cellular level, they are indispensable in maintaining cell membrane integrity and serve as signaling molecules regulating metabolic balance. An excessive lipid intake, through the socalled western-style diet, disturbs this balance and is the main cause of obesity-related diseases (or syndrome X) in developed countries (2). The development of drugs that could control circulating lipid levels, such as lowering VLDL TGs and LDL cholesterol and raising high-density lipoprotein cholesterol, has been a major focus for the pharmaceutical industry. These efforts have shown promise in treating diseases, including hyperlipidemia and cardiovascular dysfunctions.
D ietary lipids, delivered by very low-density lipoprotein (VLDL) [triglyceride (TG)-rich]
, and LDL (cholesterol rich), constitute a large portion of the body's energy source (1) . At the cellular level, they are indispensable in maintaining cell membrane integrity and serve as signaling molecules regulating metabolic balance. An excessive lipid intake, through the socalled western-style diet, disturbs this balance and is the main cause of obesity-related diseases (or syndrome X) in developed countries (2) . The development of drugs that could control circulating lipid levels, such as lowering VLDL TGs and LDL cholesterol and raising high-density lipoprotein cholesterol, has been a major focus for the pharmaceutical industry. These efforts have shown promise in treating diseases, including hyperlipidemia and cardiovascular dysfunctions.
Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear receptor superfamily and are bound and activated by fatty acids (3) . There are three subtypes in this subfamily, PPAR␣, PPAR␤͞␦, and PPAR␥, each exhibiting a distinct tissue distribution and regulating different aspects of lipid homeostasis (4, 5) . PPAR␣ plays a major role in fatty acid oxidation in liver during fasting (6, 7) , whereas PPAR␥ is important for lipid storage, adipocyte functions, and insulin sensitivity (8) (9) (10) (11) (12) . These important biological activities of PPAR␣ and PPAR␥ have later been proven responsible for the TG-lowering effect of fibrates and the insulin-sensitizing activity of thiazolidinediones, respectively (13) (14) (15) (16) . The function of ubiquitously expressed PPAR␦ was less defined until the making of genetically modified animals. Transgenic mice expressing an active form of PPAR␦ in adipocytes are resistant to diet-induced obesity due to an increased fatty acid catabolic rate (17) . Paradoxically, PPAR␦Ϫ͞Ϫ mice are also lean (18, 19) , suggesting multiple layers of regulatory mechanisms governed by this receptor.
The therapeutic potential of PPAR␦ has recently been explored through a high-affinity synthetic ligand, GW501516 (20) . Treatment with this compound in obese rhesus monkeys results in a dramatic rise in high-density lipoprotein-cholesterol along with lower levels of small-dense LDL and VLDL TGs. This observation suggests that PPAR␦ may be a drug target for coronary artery disease. Consistent with this, we have shown that LDL receptorϪ͞Ϫ mice reconstituted with PPAR␦Ϫ͞Ϫ bone marrow developed fewer atherosclerotic lesions as a result of decreased expression of genes important for inflammatory response in the macrophage (21) , a process that is critical for lesion formation. It appears that in the unliganded state, PPAR␦ sequesters repressors that would otherwise suppress the production of cytokines and chemokines. Through this unique transrepression mechanism, both ligand activation and loss of PPAR␦ release the repressors and produce antiinflammatory effects.
Although our previous study suggested a limited role of PPAR␦ in macrophage cholesterol metabolism (21), we have shown that it is a major sensor of TG-rich VLDL particles in mouse macrophages (22) . To better understand the function of PPAR␦ in VLDL homeostasis, we performed DNA array analysis to identify genes commonly regulated by a PPAR␦ synthetic agonist and VLDL in the macrophage. Our data show that, in addition to genes involved in peroxisomal and mitochondrial ␤-oxidation, activation of PPAR␦ by VLDL also induces carnitine biosynthesis. PPAR␦ does not regulate acyl-CoA synthetase and ApoB48 receptor, proteins that facilitate VLDL͞fatty acid uptake (23) . Instead, transport secretion protein 2 (TTS2) [also named desnutrin (iPLA2) and adipose TG lipase], a lipase characterized recently (24) (25) (26) , was identified as a target gene that increases the availability of fatty acids from VLDL to activate PPAR␦. Intriguingly, PPAR␦ ablation results in upregulation of target gene expression due to loss of active repression function by unliganded receptor. These results suggest that a tight regulation of fatty acid metabolism by PPAR␦ is achieved by its ability to repress basal ␤-oxidation, to sense lipid from VLDL, and subsequently to initiate a fat-burning program, thereby preventing macrophage from lipid overload.
Results
We have shown that VLDLs carry endogenous activators for PPAR␦, which in turn induces the expression of a lipidassociated protein adipose differentiation-related protein (ADRP) in the macrophage (22) . Because ADRP has been shown to be associated with cellular lipid droplets (27) , we sought to explore the role of PPAR␦ in determining the fate of lipids taken up by the macrophage (e.g., storage vs. burning). Stable RAW 264.7 cell lines (mouse monocytic cells) expressing yellow fluorescent protein control or PPAR␦ were established and treated with either vehicle, PPAR␦-specific agonist GW501516, or VLDL. DNA array analysis was performed to identify genes commonly up-regulated by synthetic ligand and VLDL. A parallel comparison revealed that these genes fell mainly into the fatty acid catabolic pathway. Northern blot analyses confirmed that most of these genes could be regulated by endogenous PPAR␦ in response to ligand, and receptor overexpression greatly enhanced levels of induction ( Fig. 1A ; compare samples minus or plus ligand). These include aldehyde dehydrogenase 9 (ALDH9, also named g-trimethylaminobutyraldehyde dehydrogenase), mitochondria carnitine palmityl transferase 1 (CPT1), carnitine͞acylcarnitine translocase (solute carrier family 25, member 20, Slc25a20) (28) , as well as peroxisomal enoyl-CoA isomerase and hydratase. ALDH9 is a key enzyme in converting lysine to carnitine (29) , which provides substrates for the carnitine shuttle system mediated by CPT1 and Slc25a20, whereas peroxisomal enoyl-CoA isomerase and hydratase play important roles in peroxisomal fatty acid ␤-oxidation. Interestingly, genes known to be involved in the initial step of this pathway, including ApoB48 receptor (a macrophage VLDL receptor) (23) , acyl-CoA synthetase 3, and acyl-CoA oxidase, were not regulated. Instead, transport secretion protein 2 (TTS2, GenBank accession no. AK031609), a recently characterized novel TG lipase, was found to be induced (24-26). In . PPAR␦ target genes identified by DNA array were examined by Northern blot hybridization. The actin probe was included as a loading control. (B) ALDH9 is a direct target gene for PPAR␦. Binding of PPARs to the putative PPRE identified from the ALDH9 promoter was examined by the gel mobility assay by using radiolabeled oligomers and in vitro translated proteins (Upper). Up to 100-fold (100ϫ) excess of unlabeled probe was included in the reaction for the binding competition experiment. Nonspecific element (NS) and PPRE from the acyl-CoA synthetase gene was included as a negative and positive control, respectively. The 5Ј regulatory region of the mouse ALDH9 gene was subsequently cloned into a luciferase reporter construct (Upper). Numbers denote the positions relative to the transcriptional initiation site. The sequence of the PPRE and its mutation is indicated. The induction of the ALDH9 promoter activity was tested in RAW cells cotransfected with PPAR␦ and the obligate heterodimer partner RXR. (C) PPAR␦ regulates TTS2 promoter activity in a PPRE-dependent manner. YFP, yellow fluorescent protein; RLU, relative luciferase unit. Concentration for GW1516, 0.1 M; VLDL plus LPL, 10 g/ml each. addition, uncoupling protein 2 (UCP2), which dissipates energy into heat, was also a target gene of PPAR␦.
Because ALDH9 (carnitine synthesis) and TTS2 (lipid mobilization) represent previously unrecognized components of the metabolic pathway targeted by PPARs, we asked whether the regulation of these two genes by PPAR␦ was a direct transcriptional event. First, the 5Ј regulatory region of the ALDH9 gene was isolated, and its activity was analyzed in a reporter transfection assay. A DR-1-type PPAR response element (PPRE) was found at the proximal region of the promoter (Ϫ366 to Ϫ354, relative to the transcriptional start site). A gel mobility-shift assay showed that radiolabeled PPRE probes could be bound by all three PPARs, whereas mutation of this site abolished the binding (Fig. 1B Upper) . The binding specificity was subsequently confirmed by the ability of unlabeled PPRE from the ALDH9 or acyl-CoA synthetase gene (a positive control) to compete for binding. In line with this, the activity of the ALDH9 promoter was induced by ligand or VLDL treatment in RAW cells, which was further enhanced by PPAR␦ cotransfection (Fig. 1B Lower) . PPRE mutation (construct Ϫ476͞M) or deletion (construct Ϫ338) resulted in loss of the inductive effect, suggesting ALDH9 is a direct PPAR␦ target. Similarly, a functional PPRE was identified in TTS2 promoter (Ϫ813 to Ϫ801, Fig. 1C ), indicating that activation of PPAR␦ by VLDL results in up-regulation of key genes in fatty acid mobilization and ␤-oxidation pathways.
As mentioned earlier, TTS2 is a recently discovered lipase (also named desnutrin, iPLA2, and adipose TG lipase), which shows a significant similarity to a putative transmembrane protein adiponutrin (43% identity) (30) . It also shares certain conserved domains with members of the patatin-like lipid acyl hydrolase family in plants. Interestingly, TTS2 and adiponutrin have been shown to exhibit both triacylglycerol lipase and acylglycerol transacylase activities (26) . Northern blot analysis demonstrated that, unlike adiponutrin, whose expression is restricted to adipocytes, TTS2 appeared to be ubiquitously expressed but enriched in brown fat, white fat, testis, and, to a lesser extent, in heart, muscle, and liver ( Fig. 2A) . Its expression was also robustly induced at an earlier stage than that of the adiponutrin during in vitro adipocyte differentiation of the 3T3-L1 cells (Fig. 2B) . To better understand the function of the TTS2͞adiponutrin family, we expressed epitope-tagged protein in CV-1 cells and performed Western blot analyses on cell fractions to determine their subcellular localization. In contrast to adiponutrin, which was detected predominately in the membrane fraction, TTS2 was mainly cytosolic (Fig. 2C) . We next sought to examine whether TTS2͞adiponutrin would affect VLDL signaling in PPAR␦ activation. This was tested in a cotransfection assay by measuring the transactivation activity of a GAL4-PPAR␦ ligand-binding domain fusion in the presence or absence of TTS2 or adiponutrin in CV-1 cells treated with VLDL. Interestingly, coexpression of TTS2 moderately increased the activity of PPAR␦, whereas adiponutrin suppressed it (Fig. 2D) , suggesting that TTS2 may facilitate fatty acid release from VLDL, thereby increasing the availability of physiological ligands for PPAR␦.
Both PPAR␣ and PPAR␥ have been shown to be activated by dietary fatty acids. To clarify whether this regulation was specific and depended on PPAR␦, we isolated peritoneal macrophages (thioglycollate-elicited) from wild-type and PPAR␦Ϫ͞Ϫ mice and treated these cells with VLDL or ligands for PPAR␣ (Wy14,643, 30 M), PPAR␦ (GW501516, 0.1 M), or PPAR␥ (rosiglitazone, 1 M). Consistent with our previous observation, PPAR␦ appeared to be the major mediator of VLDL signaling in the macrophage, because all of the genes identified by DNA array could be induced only by GW501516 and VLDL in a PPAR␦-dependent manner (Fig. 3A) . Unexpectedly, the basal levels of ADRP, ALDH9, CPT1, Slc25a20, TTS2, and enoylCoA hydratase, but not enoyl-CoA isomerase or UCP2, were up-regulated in PPAR␦ null cells. Furthermore, in the absence of PPAR␦, PPAR␥ was able to activate genes including ADRP, ALDH9, and CPT1 (Fig. 3A, on the left) , suggesting that unliganded PPAR␦ binds to target gene promoters and represses their activities.
To further confirm that up-regulation of target genes in the PPAR␦ null cells was due to derepression but not a compensatory response, we established an immortalized PPAR␦Ϫ͞Ϫ macrophage cell line. Based upon the current view of the transcriptional regulation by nuclear receptors, we anticipated that the active repression phenotype could be recapitulated by reintroducing wild-type or activation-deficient receptors (AF2 deletion, PPAR␦⌬AF2) but not DNA-binding-deficient mutant (DBD-M), into PPAR␦Ϫ͞Ϫ cells. Indeed, basal levels of target genes such as ADRP, CPT1, and Slc25a20 were suppressed in PPAR␦ and PPAR␦⌬AF2 cell lines and were not affected in DBD-M cells (compared with yellow fluorescent protein control cells, Fig. 4) . Addition of ligand released the repression only in cells expressing wild-type PPAR␦. On the other hand, the expression of enoyl-CoA isomerase and UCP2 was unchanged, as seen in the primary macrophage, implicating a promoter specificity.
The data presented above suggest that PPAR␦ regulates genes for both fatty acid release and oxidation. To determine the net effect of PPAR␦ activation, we treated macrophages with a PPAR␦ ligand for 24 h before loading with tritium-labeled oleic acid. The cellular unprocessed 3 H-oleic acid was then extracted at different time courses to determine the rate of fatty acid uptake (the first-minute time point) and accumulation (10-, 20-, and 30-min time points). Ligand treatment did not change the uptake rate but drastically decreased the amount of accumulated 3 H-oleic acid (Fig. 5A) . Consistent with the derepression of ␤-oxidation genes in PPAR␦ null cells, the cellular 3 H-oleic acid levels of PPAR␦Ϫ͞Ϫ macrophages were similar to that of the ligand-treated wild-type cells; however, the ligand effect was abolished in these cells. To further examine whether the decreased fatty acid accumulation by ligand in wild-type macrophages was due to increased fatty acid catabolism, we measured levels of ␤-oxidation product 3 H 2 O in the supernatant of cells treated with vehicle, PPAR␦ ligand, or PPAR␣ ligand. Indeed, PPAR␦ ligand-treated macrophages exhibited a 20-30% increase in the ␤-oxidation rate (Fig. 5B) , and this effect was not observed in the null cells (data not shown). PPAR␣ ligand treatment, on the other hand, did not affect 3 H 2 O production, suggesting that PPAR␣ plays a limited role in macrophage fatty acid catabolism. Collectively, these data suggest a unique regulatory mechanism by PPAR␦ in which unliganded receptors suppress fatty acid utilization through active repression of key genes in the ␤-oxidation pathway. Upon receptor activation by VLDL loading, the derepression mechanism enables a fatburning program to reduce the lipid burden of the macrophage.
Discussion
VLDL plays an important role in delivering postprandial fatty acids to the periphery as an energy source. Elevated circulating lipid levels, on the other hand, could become an insult and cause serious health problems (31) (32) (33) (34) (35) . In this study, we demonstrate that activation of PPAR␦ by VLDL leads to up-regulation of genes in three major steps of the fat-burning program (Fig. 5C ). PPAR␦ induces TTS2 to potentiate fatty acid release, which is accompanied by increased production of L-carnitine through the converting enzyme ALDH9. Very long-chain fatty acids require an extra chain-shortening step in the peroxisome where enoylCoA dehydrogenase and hydratase catalyze rate-limiting steps of the oxidation reaction. Carnitine is then conjugated to acyl-CoA by CPT1 and transported into mitochondria by Slc25a20. Inside the mitochondria, fatty acids are oxidized to generate energy, whereas UCPs can further dissipate energy to produce heat. Given its ubiquitous expression pattern, PPAR␦ appears to be the key VLDL mediator coordinating the expression of genes that control the body's energy expenditure and, most importantly, protecting macrophages at the vessel wall from lipid overload.
The identification of the TTS2͞adiponutrin family implicates a new category of proteins involved in lipid mobilization and͞or storage. Despite their structural similarity, TTS2 and adiponutrin exhibit distinct tissue distribution, cellular localization, and functions. Adiponutrin is confined to adipocytes, and the time course of its expression during 3T3-L1 adipocyte differentiation coincides with that of perilipin, a marker for mature adipocytes that inhibits basal lipolysis. In contrast, cell fractionation and immunohistochemical staining showed that TTS2 is evenly distributed in the cytosol and only partially overlapped with small lipid droplets when overexpressed in CV-1 cells (Fig. 2 and data not shown). Although TTS2 was characterized as a lipase, there was a great discrepancy in its reported tissue expression pattern, cellular localization, and lipase activity among different studies, including the current one (24) (25) (26) . In particular, both TTS2 and adiponutrin have also been shown to possess acylglycerol transacylase activity, which incorporates fatty acid into TG (26) . Judging from their ability to modulate VLDL-mediated PPAR␦ activation, it is likely that members of this family determine the availability of free fatty acids through their dual lipase͞ transacylase activity, in which membrane-bound adiponutrin directs lipids to a route for long-term storage while cytosolic TTS2 mobilizes fatty acids for energy usage.
Although TG-rich lipoproteins have been implicated as independent risk predictors of atherosclerosis (31) (32) (33) (34) (35) (36) , the relevance of regulated macrophage ␤-oxidation in the pathogenesis of this disease is currently unclear. It is possible the reduced fat burden by itself is beneficial. The regulation of UCP2 by PPAR␦, however, may provide additional antiatherogenic effects. Members of the UCP family are believed to play an important role in adaptive thermogenesis. Interestingly, UCP2 knockout mice have an exaggerated inflammatory response and are resistant to infection but show no differences in body weight and reaction to cold exposure compared with wild-type animals (37) . Reciprocally, transgenic mice overexpressing UCP2 exhibit reduced proinflammatory cytokine production by lipopolysaccharide challenge (38) . It appears that one major function of UCP2 in the macrophage is to suppress inflammation through modulating levels of reactive oxygen species. The ability of PPAR␦ to induce the expression of UCP2 and genes in the ␤-oxidation pathway thus provides a means for the receptor, in response to lipid insult, to regulate both lipid metabolism and inflammation, which are the two key components of atherogenesis.
It has been shown that PPAR␦-null mice exhibit a lean phenotype (18, 19) . The observed up-regulation of ␤-oxidation genes due to loss of repression in the PPAR␦Ϫ͞Ϫ cells could be a potential mechanism for the reduced fat mass. This active repression activity enables PPAR␦ to function as an energy sensor and a metabolic switch, which suppresses fatty acid utilization when circulating lipids are scarce while inducing fatty acid catabolism when lipids are abundant. This observation suggests that, in addition to cardiovascular disease, PPAR␦ may also play a role in the development of diabetes, because a preference for fatty acid utilization over glucose is thought to contribute to the onset of insulin resistance (39, 40) . Populationbased polymorphism studies will reveal whether loss-of-function mutations result in a bias toward fatty acid usage (due to loss of repression) and cause incidents of diabetes. Pharmacological activation of the receptor, however, is likely to have a different outcome, given that transcriptional activation appears to exceed derepression in turning on gene expression (Figs. 3 and 4) . In addition, ligand treatment could also activate certain genes that are not normally suppressed by unliganded receptors (e.g., UCP2 and enoyl-CoA isomerase). Although the intimate relation between diabetes and coronary artery disease has been well established, a molecular link between insulin and͞or fatty acid homeostasis of the macrophage and atherosclerosis remains to be built. The identification of PPAR␦ as a macrophage VLDL sensor and inflammation modulator at atherosclerotic lesions implicates PPAR␦ as a strong candidate for this link and a therapeutic target for both diseases.
Materials and Methods
DNA Array Analysis. cDNA clones were spotted on Amersham Pharmacia Biotech Type 7 slides and hybridized to Cy3-and Cy5-labeled probes. Clone collection, hybridization condition, and data analysis were as described (41) . Slides were produced and analyzed by The Salk Institute Laboratory of Functional Genomics.
Cell Culture. RAW 264.7 cells were maintained in DMEM͞10% FBS. Stable PPAR␦-expressing lines were described previously (21) . Peritoneal macrophages were isolated 3 days after thioglycollate challenge from wild-type SV129 and PPAR␦Ϫ͞Ϫ (SV129 background) mice. Cells were cultured in RPMI medium 1640͞ 10% FBS. An immortalized PPAR␦Ϫ͞Ϫ monocytic cell line was derived from PPAR␦Ϫ͞Ϫ bone marrow according to an established protocol and maintained in DMEM͞10% FBS. Cells expressing wild-type and mutant receptors were established by using the same strategy as for RAW cells. The DNA-binding-deficient mutant was constructed by mutating the first cysteine in the first zinc finger to alanine. Cells were treated with ligand for 24 h before harvesting. The 3T3-L1 differentiation procedure was as described (17) . VLDL was purchased from Intracel (Rockville, MD). RNAs were isolated by using the TRIzol reagent (Invitrogen).
Reporter Constructs and Cotransfection Experiment. 5Ј RACE was performed to define the transcriptional initiation sites of the mouse ALDH9 and TTS2 gene. The 5Ј untranslated region was then used for database search (www.ensembl.org) to identify regulatory sequences. The promoter region was PCR-amplified and cloned into the pGL3-basic vector (Promega). Promoter constructs were transfected into RAW cells, together with control vectors or expression vectors for PPAR␦ and retinoid X receptor (RXR)␣ (pCMX-mPPAR␦ and pCMX-RXR␣) and a ␤-galactosidase internal control. Cells were harvested 48 h after transfection (24 h after ligand treatment) for luciferase assays. Gel Mobility-Shift Assay and Cell Fractionation. The gel-shift assay was performed as described (22) . Briefly, in vitro translated proteins encoding PPAR␣, PPAR␥, and PPAR␦ were incubated with radiolabeled oligomers containing wild-type (5Ј-TATCTAGGCCAAAGGTCTTCCAG-3Ј) or mutant PPRE (5Ј-TATCTAGGCCA A AGATCT TCCAG-3Ј) from the ALDH9 gene. For cold competition experiments, excess amounts of unlabeled probes were included. These reactions were then analyzed in a nondenaturing gel.
CV-1 cells were transfected with either FLAG-tagged TTS2 (pCMX-FLAG-TTS2) or FLAG-tagged adiponutrin (pCMX-FLAG-adiponutrin). Cell fractionation was performed by using a Subcellular Proteome Extraction Kit (Calbiochem) according to the manufacturer's instructions. An equal amount of protein from each fraction was loaded for Western analyses by using antibodies against FLAG (Sigma), cyp450 reductase, and HSP 90 (Santa Cruz Biotechnology).
Fatty Acid Uptake and ␤-Oxidation Assay. Macrophages were plated at a density of 2 ϫ 10 5 per well in a 12-well format. Cells were incubated with or without ligand for 24 h and washed twice in the Krebs-Ringer buffer. Cells were loaded with a fatty acid solution containing 1% BSA, 100 M oleic acid, and 3 H oleic acid [2 Ci͞well (1 Ci ϭ 37 GBq)]. Reactions were terminated by washing cells with an ice-cold stop solution (Krebs-Ringer buffer containing 200 M phloretin). Cells were lysed in 0.5 ml of 0.1 M NaOH. Aliquots of lysates were used to determine protein concentrations and amounts of unprocessed 3 H oleic acid. ␤-oxidation assay was conducted as described (17) .
